mRNA and Gene Editing Offer Hope to Children with Rare Diseases
Dr. Coller discusses how the science to treat rare diseases now exists, but the real barrier is a regulatory and commercial infrastructure never designed for bespoke, single-patient molecular therapies. He offers the view of gene editing as "molecular surgery" rather than a pharmaceutical drug -- a view that could enable the scaling of these breakthroughs beyond one-off miracles.





